Skip to main content

Table 5 Immunohistochemical patterns before and after neoadjuvant chemotherapy with docetaxel plus epirubicin in sixty breast cancer patients.

From: HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination

  Pre-chemotherapy N (%) Post-chemotherapy N (%) p Dif. (%)
p53 + 18 (30) 8 (14.5) 0.039 13.2
p21 + 13 (21.6) 5 (9.2) 0.021 14.81
HER-2 + 11 (18.3) 7 (12.5) 0.12 NS
  1. N = number of patients; Dif. = difference between before and after chemotherapy – McNemar test; NS = not significant.
\